nasdaq:jazz
|
https://www.indeed.com/cmp/jazz-pharmaceuticals
|
Aug 29th, 2022 12:00AM
|
Open
|
Jazz Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.
|
RRv1_1B_5B
|
Palo Alto, CA
|
Bruce C. Cozadd
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41.00
|
41.00
|
3.40
|
3.60
|
2.90
|
3.10
|
3.40
|
11.00
|
About two weeks
|
11.00
|
MEDIUM
|
11.00
|
FAVORABLE
|
|
|
|
Aug 29th, 2022 12:08PM
|
Aug 29th, 2022 12:08PM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/gw-pharmaceuticals
|
Aug 29th, 2022 12:00AM
|
Open
|
GW Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
GW Pharmaceutical’s vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates.
Epidiolex is GW’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).
We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.
|
RRv1_25M_100M
|
Salisbury, UK
|
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 29th, 2022 12:08PM
|
Aug 29th, 2022 12:08PM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/gw-pharmaceuticals
|
Aug 28th, 2022 12:00AM
|
Open
|
GW Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
GW Pharmaceutical’s vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates.
Epidiolex is GW’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).
We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.
|
RRv1_25M_100M
|
Salisbury, UK
|
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 28th, 2022 05:07AM
|
Aug 28th, 2022 05:07AM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/jazz-pharmaceuticals
|
Aug 28th, 2022 12:00AM
|
Open
|
Jazz Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.
|
RRv1_1B_5B
|
Palo Alto, CA
|
Bruce C. Cozadd
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41.00
|
41.00
|
3.40
|
3.60
|
2.90
|
3.10
|
3.40
|
11.00
|
About two weeks
|
11.00
|
MEDIUM
|
11.00
|
FAVORABLE
|
|
|
|
Aug 28th, 2022 05:07AM
|
Aug 28th, 2022 05:07AM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/gw-pharmaceuticals
|
Aug 27th, 2022 12:00AM
|
Open
|
GW Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
GW Pharmaceutical’s vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates.
Epidiolex is GW’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).
We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.
|
RRv1_25M_100M
|
Salisbury, UK
|
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 27th, 2022 04:27AM
|
Aug 27th, 2022 04:27AM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/jazz-pharmaceuticals
|
Aug 27th, 2022 12:00AM
|
Open
|
Jazz Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.
|
RRv1_1B_5B
|
Palo Alto, CA
|
Bruce C. Cozadd
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41.00
|
41.00
|
3.40
|
3.60
|
2.90
|
3.10
|
3.40
|
11.00
|
About two weeks
|
11.00
|
MEDIUM
|
11.00
|
FAVORABLE
|
|
|
|
Aug 27th, 2022 04:27AM
|
Aug 27th, 2022 04:27AM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/jazz-pharmaceuticals
|
Aug 25th, 2022 12:00AM
|
Open
|
Jazz Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.
|
RRv1_1B_5B
|
Palo Alto, CA
|
Bruce C. Cozadd
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41.00
|
41.00
|
3.40
|
3.60
|
2.90
|
3.10
|
3.40
|
11.00
|
About two weeks
|
11.00
|
MEDIUM
|
11.00
|
FAVORABLE
|
|
|
|
Aug 25th, 2022 09:06AM
|
Aug 25th, 2022 09:06AM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/gw-pharmaceuticals
|
Aug 25th, 2022 12:00AM
|
Open
|
GW Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
GW Pharmaceutical’s vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates.
Epidiolex is GW’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).
We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.
|
RRv1_25M_100M
|
Salisbury, UK
|
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 25th, 2022 09:06AM
|
Aug 25th, 2022 09:06AM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/jazz-pharmaceuticals
|
Aug 23rd, 2022 12:00AM
|
Open
|
Jazz Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.
|
RRv1_1B_5B
|
Palo Alto, CA
|
Bruce C. Cozadd
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41.00
|
41.00
|
3.40
|
3.60
|
2.90
|
3.10
|
3.40
|
11.00
|
About two weeks
|
11.00
|
MEDIUM
|
11.00
|
FAVORABLE
|
|
|
|
Aug 23rd, 2022 11:00AM
|
Aug 23rd, 2022 11:00AM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:jazz
|
https://www.indeed.com/cmp/gw-pharmaceuticals
|
Aug 23rd, 2022 12:00AM
|
Open
|
GW Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
GW Pharmaceutical’s vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates.
Epidiolex is GW’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).
We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.
|
RRv1_25M_100M
|
Salisbury, UK
|
|
|
|
4.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 23rd, 2022 11:00AM
|
Aug 23rd, 2022 11:00AM
|
Jazz Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|